Vanderbilt Vaccine Center
Jun. 14, 2019—Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies.
Jun. 6, 2019—VUMC has joined an international effort to streamline and accelerate development of vaccines and other treatments against a growing worldwide surge of deadly and debilitating viral infections.
May. 16, 2019—The flu mutates so quickly that we need a new vaccine every year, but Vanderbilt scientists have found a vulnerable part of the virus that doesn't mutate as much.
Apr. 30, 2019—The Vanderbilt Vaccine Center Seminar Series presents Brandon DeKosky, assistant professor of chemical engineering and pharmaceutical chemistry at the University of Kansas, on Monday, May 6.
Feb. 21, 2019—A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.
Feb. 13, 2019—Using sophisticated gene sequencing and computing techniques, Vanderbilt researchers have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection.
Jan. 31, 2019—James Crowe Jr. and colleagues have developed a new computational method that may allow researchers to develop flu antibodies that can protect against more strains of the disease.
Jan. 25, 2019—Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.
Dec. 7, 2018—Research led by James Crowe, Jr., could lead to the first effective treatment for this dangerous mosquito-transmitted infection.
Aug. 30, 2018—The discovery of these antibodies could significantly improve the diagnosis and treatment of the leading cause of stomach illness in the world.
Aug. 6, 2018—The computer-aided design and engineering of antibodies and vaccine candidates that can neutralize viral scourges like influenza and Ebola will be the topic of an Aug. 17 poster session presented by the Vanderbilt Center for Structural Biology and the Vanderbilt Vaccine Center.
Jul. 19, 2018—Researchers led by James Crowe Jr. are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans. The hope is that the antibodies — like heat-seeking missiles — would seek out and destroy the viruses before they can wreak havoc in the body.